Skip to content

house · Committee report

H. Rept. 118-104

ANIMAL DRUG AND ANIMAL GENERIC DRUG USER FEE AMENDMENTS OF 2023

2023-06-09

Committees

Associated legislation

Text

Purpose and Summary

H.R. 1418 reauthorizes provisions of the Animal Drug User Fee Act (ADUFA) and the Animal Generic Animal Drug User Fee Act (AGDUFA) through fiscal year (FY) 2028. Specifically, the bill would allow the Food and Drug Administration (FDA) to continue to collect and obligate user fees, paid by regulated industry to supplement Congressional appropriations, for the review of animal drugs and animal generic drugs. It also includes provisions that improve upon the review and development of animal health products and support activities regarding the development and stewardship of animal antimicrobials.

Background and Need for Legislation

The Federal Food, Drug, and Cosmetic Act (FFDCA) provides FDA authorities over the review and regulation of brand-name (pioneer) and generic animal drugs. These authorities are funded through annual discretionary appropriations and further supplemented by user fees paid by regulated industry. The revenue generated by user fees supports FDA in providing greater regulatory certainty to animal application sponsors and in improving upon the animal product development and review process. In determining recommended fee amounts, FDA commits to meet certain performance and application review goals, which are negotiated with the regulated industry and submitted to Congress. Authorities to collect user fees for pioneer animal drugs were first provided for by Congress in the Animal Drug User Fee Act of 2003 (referred to as ADUFA I, P.L. 108-130) for FY2004 to FY2008. The user fee program established under ADUFA I was modeled after FDA's prescription drug user fee program, which had improved the timeliness and predictability of FDA's review of certain human drugs. Congress later granted FDA authorities over the review of generic animal drugs for FY2009 in the Animal Generic Drug User Fee Act of 2008 (AGDUFA I, P.L. 110- 316), which was passed alongside the first reauthorization of ADUFA II. Authorities for AGDUFA have been reauthorized three times since and will sunset September 30, 2023. Previous reauthorizations of ADUFA and AGDUFA have included additional provisions intended to improve upon FDA's review and regulation of certain animal health products. This legislation proposes several policies to build upon the programs, including new reporting requirements to enhance transparency into the review and reauthorization processes, amendment of the `major species' definition to support utilization of approval pathways for unmet animal health needs, and codification of reporting dates for FDA on activities relating to stewardship over animal antimicrobials. ADUFA IV and AGDUFA III will expire at the end of FY2023 and must be reauthorized for FDA to continue collecting and obligating user fee towards the review of animal drug and generic animal drug applications. This legislation will reauthorize both programs through FY2028 and support the implementation of additional provisions considered within this legislation.

Committee Action

On March 30, 2023, the Subcommittee on Health held a hearing on H.R. 1418. The Subcommittee received testimony from: Ms. Tracey Forfa, J.D., Director, Center for Veterinary Medicine (CVM), U.S. Food and Drug Administration (FDA); Ms. Rachel Cumberbatch, DVM, Director, Regulatory Affairs, Animal Drugs, Animal Health Institute (AHI); Ms. Stephanie Batliner, Chair, Generic Animal Drug Alliance (GADA); and Ms. Lori Teller, DVM, President, American Veterinary Medical Association (AVMA) On May 17, 2023, the Subcommittee on Health met in open markup session and forwarded H.R. 1418, as amended, to the full Committee by a record vote of 29 yeas and 0 nays. On May 24, 2023, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 1418, as amended, favorably reported to the House by a record vote of 49 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R 1418 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to reauthorize the FDA animal drug user fee programs and improve the review of products regulated by FDA. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 1418 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, (1) the following hearing was used to develop or consider H.R. 1418: On March 30, 2023, the Subcommittee on Health held a hearing on H.R. 1418. The Subcommittee received testimony from: Ms. Tracey Forfa, J.D., Director, Center for Veterinary Medicine (CVM), U.S. Food and Drug Administration (FDA); Ms. Rachel Cumberbatch, DVM, Director, Regulatory Affairs, Animal Drugs, Animal Health Institute (AHI); Ms. Stephanie Batliner, Chair, Generic Animal Drug Alliance (GADA); and Ms. Lori Teller, DVM, President, American Veterinary Medical Association (AVMA). Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 1418 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation TITLE I: FEES RELATING TO ANIMAL DRUGS Section 1. Short title Section 1 provides a short title for the legislation, the ``Animal Drug and Animal Generic User Fee Amendments of 2023.'' Section 2. Table of contents Section 2 provides a table of contents for the legislation. TITLE I: FEES RELATING TO ANIMAL DRUGS Section 101. Short title; finding Section 101 establishes a short title for Title I, the ``Animal Dug User Fee Amendments of 2023.'' It also dedicates fees authorized by this title toward expediting the animal drug development process and review of animal drug applications as set forth by statute. Section 102. Definitions Section 102 adds to the definition of ``process for the review of abbreviated applications for new animal drugs'' activities necessary to implement US-EU and US-UK mutual recognition agreements, with respect to new animal drug products subject to review. Section 103. Authority to assess and use animal drug fees Section 103 reauthorizes FDA's animal drug user fee program through 2028 and updates the base revenue amount for ADUFA V. It also provides for the negotiated resource levels and updated fee-setting process. Section 104. Reauthorization; reporting requirements Section 104 reauthorizes FDA reporting requirements to Congress relating to the agency's progress in implementing its user fee authorities and in meeting performance goals, as set forth in the commitment letter submitted to the Congressional Record. Section 105. Savings clause Section 105 preserves authorities to assess fees pursuant to part 4 of subchapter C of chapter VII of FFDCA, effective until enactment of this title. Section 106. Effective date Section 106 provides that amendments made by this title shall take effect October 1, 2023, or the date of enactment, whichever is later. Section 107. Sunset dates Section 107 provides that reporting requirements and authorities to collect and assess user fees for the process of the review of new animal drugs shall cease to be effective October 1, 2028. TITLE II: FEES RELATING TO GENERIC ANIMAL DRUGS Section 201. Short title; finding Section 201 establishes a short title for Title II, ``Animal Generic Drug User Fee Amendments of 2023.'' It also dedicates fees authorized by this title toward expediting the generic new animal drug development process and review of abbreviated applications for generic new animal drug applications as set forth by statute. Section 202. Authority to assess and use generic new animal drug fees Section 202 reauthorizes FDA's generic animal drug user fee program through 2028 and updates the base revenue amount for AGDUFA IV. It establishes a new fee type for generic investigational new animal drug files and provides for negotiated resource levels. It also adds to the definition of ``process for the review of abbreviated applications for generic new animal drugs'' activities necessary to implement US-EU and US-UK mutual recognition agreements with respect to generic new animal drug products subject to review. Section 203. Reauthorization; reporting requirements Section 203 reauthorizes FDA reporting requirements to Congress relating to the agency's progress in implementing its user fee authorities and in meeting performance goals, as set forth in the commitment letter submitted to the Congressional Record. Section 204. Savings clause Section 204 preserves authorities to assess fees pursuant to part 5 of subchapter C of chapter VII of FFDCA, effective until enactment of this title. Section 205. Effective date Section 205 provides that amendments made by this title shall take effect October 1, 2023, or the date of enactment, whichever is later. Section 206. Sunset dates Section 206 provides that reporting requirements and authorities to assess user fees for the process of the review of generic new animal drugs shall cease to be effective October 1, 2028. TITLE III: SUPPORTING ANIMAL AND HUMAN HEALTH Section 301. Reporting requirements Section 301 updates requirements for FDA reporting to Congress to include data regarding the review process for animal drug applications and sponsor requests for in-person, face-to-face meetings in FY2024 and FY2025. Section 302. Major species Section 302 amends the definition of ``major species'' in the Federal Food, Drug, and Cosmetic Act to allow for the Secretary, through rulemaking, to add or remove species from the definition. Section 303. Antimicrobial resistance Section 303 requires FDA, not later than December 31, 2023, to submit to Congress a report describing activities conducted by FDA's Center for Veterinary Medicine (CVM) during FY2019 through FY2023 to support antimicrobial stewardship in veterinary settings. FDA must also report its goals to support antimicrobial stewardship in veterinary settings, activities it plans to execute in FY2024 through FY2028 to support those goals, and metrics it plans to use to evaluate progress toward those goals. Section 303 also requires FDA to submit, not later than 120 days after the end of each fiscal year in which animal drug user fees are collected, annual progress reports regarding antimicrobial stewardship and activities undertaken to incentivize the development of new animal antimicrobials. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): FEDERAL FOOD, DRUG, AND COSMETIC ACT * * * * * * * CHAPTER II--DEFINITIONS Sec. 201. For the purposes of this Act-- (a)(1) The term ``State'', except as used in the last sentence of section 702(a), means any State or Territory of the United States, the District of Columbia, and the Commonwealth of Puerto Rico. (2) The term ``Territory'' means any Territory or possession of the United States, including the District of Columbia, and excluding the Commonwealth of Puerto Rico and the Canal Zone. (b) The term ``interstate commerce'' means (1) commerce between any State or Territory and any place outside thereof, and (2) commerce within the District of Columbia or within any other Territory not organized with a legislative body. (c) The term ``Department'' means the Department of Health and Human Services. (d) The term ``Secretary'' means the Secretary of Health and Human Services. (e) The term ``person'' includes individual, partnership, corporation, and association. (f) The term ``food'' means (1) articles used for food or drink for man or other animals, (2) chewing gum, and (3) articles used for components of any such article. (g)(1) The term ``drug'' means (A) articles recognized in the official United States Pharmacopeia, official Homeopathic Pharmacopeia of the United States, or official National Formulary, or any supplement to any of them; and (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and (C) articles (other than food) intended to affect the structure or any function of the body of man or other animals; and (D) articles intended for use as a component of any articles specified in clause (A), (B), or (C). A food or dietary supplement for which a claim, subject to sections 403(r)(1)(B) and 403(r)(3) or sections 403(r)(1)(B) and 403(r)(5)(D), is made in accordance with the requirements of section 403(r) is not a drug solely because the label or the labeling contains such a claim. A food, dietary ingredient, or dietary supplement for which a truthful and not misleading statement is made in accordance with section 403(r)(6) is not a drug under clause (C) solely because the label or the labeling contains such a statement. (2) The term ``counterfeit drug'' means a drug which, or the container or labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, or device, or any likeness thereof, of a drug manufacturer, processor, packer, or distributor other than the person or persons who in fact manufactured, processed, packed, or distributed such drug and which thereby falsely purports or is represented to be the product of, or to have been packed or distributed by, such other drug manufacturer, processor, packer, or distributor. (h)(1) The term ``device'' (except when used in paragraph (n) of this section and in sections 301(i), 403(f), 502(c), and 602(c)) means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is-- (A) recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them, (B) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (C) intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes. The term ``device'' does not include software functions excluded pursuant to section 520(o). (2) The term ``counterfeit device'' means a device which, or the container, packaging, or labeling of which, without authorization, bears a trademark, trade name, or other identifying mark or imprint, or any likeness thereof, or is manufactured using a design, of a device manufacturer, processor, packer, or distributor other than the person or persons who in fact manufactured, processed, packed, or distributed such device and which thereby falsely purports or is represented to be the product of, or to have been packed or distributed by, such other device manufacturer, processor, packer, or distributor. (i) The term ``cosmetic'' means (1) articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance, and (2) articles intended for use as a component of any such articles; except that such term shall not include soap. (j) The term ``official compendium'' means the official United States Pharmacopeia, official Homeopathic Pharmacopeia of the United States, official National Formulary, or any supplement to any of them. (k) The term ``label'' means a display of written, printed, or graphic matter upon the immediate container of any article; and a requirement made by or under authority of this Act that any word, statement, or other information appear on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any there be, of the retail package of such article, or is easily legible through the outside container or wrapper. (l) The term ``immediate container'' does not include package liners. (m) The term ``labeling'' means all labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article. (n) If an article is alleged to be misbranded because the labeling or advertising is misleading, then in determining whether the labeling or advertising is misleading there shall be taken into account (among other things) not only representations made or suggested by statement, word, design, device, or any combination thereof, but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result from the use of the article to which the labeling or advertising relates under the conditions of use prescribed in the labeling or advertising thereof or under such conditions of use as are customary or usual. (o) The representation of a drug, in its labeling, as an antiseptic shall be considered to be a representation that it is a germicide, except in the case of a drug purporting to be, or represented as, an antiseptic for inhibitory use as a wet dressing, ointment, dusting powder, or such other use as involves prolonged contact with the body. (p) The term ``new drug'' means-- (1) Any drug (except a new animal drug or an animal feed bearing or containing a new animal drug) the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling thereof, except that such a drug not so recognized shall not be deemed to be a ``new drug'' if at any time prior to the enactment of this Act it was subject to the Food and Drugs Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use; or (2) Any drug (except a new animal drug or an animal feed bearing or containing a new animal drug) the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions. (q)(1)(A) Except as provided in clause (B), the term ``pesticide chemical'' means any substance that is a pesticide within the meaning of the Federal Insecticide, Fungicide, and Rodenticide Act, including all active and inert ingredients of such pesticide. Notwithstanding any other provision of law, the term ``pesticide'' within such meaning includes ethylene oxide and propylene oxide when such substances are applied on food. (B) In the case of the use, with respect to food, of a substance described in clause (A) to prevent, destroy, repel, or mitigate microorganisms (including bacteria, viruses, fungi, protozoa, algae, and slime), the following applies for purposes of clause (A): (i) The definition in such clause for the term ``pesticide chemical'' does not include the substance if the substance is applied for such use on food, or the substance is included for such use in water that comes into contact with the food, in the preparing, packing, or holding of the food for commercial purposes. The substance is not excluded under this subclause from such definition if the substance is ethylene oxide or propylene oxide, and is applied for such use on food. The substance is not so excluded if the substance is applied for such use on a raw agricultural commodity, or the substance is included for such use in water that comes into contact with the commodity, as follows: (I) The substance is applied in the field. (II) The substance is applied at a treatment facility where raw agricultural commodities are the only food treated, and the treatment is in a manner that does not change the status of the food as a raw agricultural commodity (including treatment through washing, waxing, fumigating, and packing such commodities in such manner). (III) The substance is applied during the transportation of such commodity between the field and such a treatment facility. (ii) The definition in such clause for the term

Source: https://api.congress.gov/v3/committee-report/118/hrpt/104